Sometimes Twitter is just amazing. Last night, I tweeted that The Medicines Company's oritavancin -- a hospital antibiotic I've been following since it was owned by Intermune, which divested it in 2005 -- had just been approved. (Like several other drugs, including Cubist's blockbuster Cubicin, it was invented at Eli Lilly then licensed out when Lilly left antibiotics.) Then I got this response about a competiting product, Dalvance from Durata, from infectious disease consultant Peter Bornstein. Among those who responded: Atlas Ventures' Mike Gladstone, a venture capitalist in the biotech space. .
I have no idea if Bornstein is right about the pricing here. But I'm putting the whole thing here because I want to save it.
@matthewherper Fast on the heels of dalbavancin. I wonder what the price?. I was looking at dalba for a patient. Cost: $3K for 1 dose.
— Peter Bornstein (@spidadoc1) August 7, 2014
@MikeNGladstone @matthewherper Outpatient, yes. Inpatient, no. Hospitals get capitated fees--once patient iadmitted, they won't want to pay.
— Peter Bornstein (@spidadoc1) August 7, 2014
@mpatel415 @MikeNGladstone @matthewherper "May" is a much more uncertain word than "Will". Doubt dalba will shorten inpt stays.
— Peter Bornstein (@spidadoc1) August 7, 2014
